|Videos|November 18, 2020

Sharing the Results: ALKS 3831

ALKS 3831, if approved by the FDA, could be a promising new treatment option for schizophrenia or bipolar I disorder.

Adam Simmons, MPH, shares results and insights from the Enlightened II study for Alkermes' drug, ALKS 3831.

To read more about ALKS 3831, see FDA Advisory Committee Votes in Favor of ALKS 3831.

Mr Simmons is the Director of Clinical Program Management at Alkermes.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe Now!

Related Content

Latest CME

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?
Video

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Michael Asbach, DMSc, PA-C; Erin Crown, MHS, PA-C, Psych-CAQ

View more
Optimizing Care for Patients With Tardive Dyskinesia
Video

Optimizing Care for Patients With Tardive Dyskinesia

Amber Hoberg, MSN, APRN, PMHNP-BC; Erin Crown, PA-C, Psych-CAQ

View more
Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia
Video

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

Jonathan Meyer, MD; Jacob Hanaie, PharmD, APh, BCPP; Sanjai Rao, MD, DFAPA

View more